glutathione bromopyruvic acid reaction Reductase (GR) Assay Kit (ab83461) 3-Bromopyruvate-Conjugated Nanoplatform-Induced Pro-Death Autophagy for

Description

Qualtrics, X

10.1016/j.freeradbiomed.2012.02.043 65

Their removal from Category 2 doesnt guarantee future access and the peptides now sit in regulatory limbo, awaiting the July ruling

M.AuingerP.WeitzmanM

What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy